A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 12/10/2013
TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase. By admin / 12/11/2012
